Background: Recent meta-analysis revealed that elevated presynaptic striatal dopaminergic function is a robust feature of psychosis like schizophrenia. Considering increased dopaminergic capacity in psychotic disorders, it is not surprising that antipsychotic drugs, which primarily block dopaminergic neurotransmission, are mostly effective in the treatment of psychosis. However, it remains obscure what would happen to presynaptic dopaminergic function with antipsychotic treatment. This is an important issue addressing whether the current antipsychotic drugs are correcting the primary dopaminergic abnormality or not. In addition, the issue can give a clue regarding the mechanism of relapse in psychotic disorders. Methods: We measured presynaptic dopamine capacity using [18F]DOPA PET before and after the antipsychotic discontinuation in first episode psychosis. The binding potentials of [11C]raclopride were also measured after the discontinuation. Healthy controls had [18F]DOPA and [11C]raclopride scans at the corresponding date. First episode psychosis patients were carefully monitored in the aspects of symptomatic aggravations. Results: The presynaptic dopamine capacity and the density of dopamine receptors showed significant group effect and the interaction between group and time (p<0.005) Discussion: Dopaminergic function seems to play a critical role in relapse of first episode psychosis.
Background: Approximately one-third of schizophrenia patients will not respond adequately to conventional antipsychotic treatment; termed treatment-resistant schizophrenia (TRS). The only antipsychotic recommended for this group is clozapine, which may have unique efficacy in improving residual symptoms. The biological mechanisms underlying its efficacy are poorly understood. Previous studies have examined the effects of clozapine on regional cerebral blood flow (rCBF) using radiotracer approaches in relatively small samples of patients, showing, in particular, frontal and limbic perfusion changes1,2,3. In this study, we evaluate the effects of clozapine on rCBF, measured with a non-invasive MRI technique -pulsed continuous arterial spin labelling (pCASL) -which does not require radiotracer injection, as part of an ongoing study to identify neuroimaging predictors and mediators of clozapine response. Methods: Participants ≥18 years of age with TRS were recruited at the Institute of Psychiatry, Psychology & Neuroscience, Kings College London (UK). TRS status was ascertained by the documented failure to respond to at least two different antipsychotic trials of adequate length. Participants were either clozapine-naïve or had not taken clozapine for at least three months prior to the baseline MRI scan. After baseline MRI, clozapine was administered as part of routine clinical care for 12 weeks, after which a second MRI scan was performed. Symptomatic response was defined as a reduction of 20% of the Positive and Negative Syndrome Scale (PANSS)4 score and non-response was defined as <20% decrease in PANSS score. pCASL data was acquired on a General Electric 3 Tesla MR-750 MR scanner. Arterial blood was labelled using a long, adiabatic (1.8 seconds) radio frequency pulse. After a post-labelling delay of 2.025s, perfusion images were acquired with a 3D Fast Spin Echo spiral multi-shot readout (TE 32ms/TR = 5500ms; ETL = 64). Cerebral blood flow (CBF) maps were computed with a spatial resolution of 2x2x3mm, in a total acquisition time of less than 6min. CBF maps were pre-processed using the Automatic Software for ASL processing (ASAP) toolbox5. Changes in rCBF after 12 weeks of clozapine were analysed in a full factorial ANOVA design, using SPM 12 (www.fil.ion.ucl.ac.uk/spm). Clusters of significant CBF changes were assessed at p<0.05 after Family-Wise Error correction for cluster extent, using a cluster-forming threshold of T>2.74.
Results: This is an interim analysis of 24 patients who completed both scans. Contrasts were examined at a whole brain, assumption-free voxelwise analysis, restricted to grey matter and co-varied for global perfusion. Clozapine administration significantly decreased perfusion in the medial frontal gyrus. There was also a significant response x time interaction, centred in the left posterior cerebellum and extending to the bilateral visual cortex and right precuneus. Discussion: These interim results indicate that pCASL may be able to identify brain regions in which activity is modulated by clozapine administration as well as areas that may mediate symptomatic improvement. A key question for future analyses will be the degree to which rCBF may predict symptomatic response to clozapine, as the ability to predict a good likelihood of response could enable earlier clozapine initiation. 
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Background: As a refractory negative symptom, social anhedonia is prevalent in people with schizophrenia spectrum disorders. Furthermore, schizophrenia is conclusively correlated with disorganized functional brain network reflected by topological profile. However, studies on the relationship between social anhedonia and topological properties of functional brain network in schizophrenia were limited to a large extent. In the present study we explored the neurofunctional mechanism of social anhedonia in schizophrenia from the perspective of topological profile of functional brain network. Methods: Six-minute resting-state fMRI images were acquired from 65 patients with schizophrenia in a 3T SIMENS scanner. Topological properties of functional brain network derived from the resting-state fMRI image, including clustering coefficient, global efficiency and small-worldness were calculated. The social anhedonia of each participant was measured with the Chapman Social Anhedonia Scale. Due to the wide-range of duration of illness in patients with schizophrenia, we included the duration of illness, social anhedonia and their interaction into a generalized linear model to predict the three topological properties, with gender, age and education years as covariates.
Results:
We found that the clustering coefficient of brain functional network in schizophrenia increased (p = 0.032, beta = 0.000194 at the minimum network sparsity 35% in which all the nodes were fully connected), whereas the global efficiency decreased (p = 0.005, beta = -0.000022), as the progression of schizophrenia. Although the main effect of social anhedonia in predicting both the clustering efficient and the global efficiency were not significant, its interaction with the duration of illness was significant (p = 0.021, beta = 0.000038 for the clustering coefficient; p = 0.023, beta = -0.000003 for the global efficiency). Discussion: With the development of schizophrenia, the increase of clustering coefficient and decrease of global efficiency of functional brain network may reflect the pathophysiology of schizophrenia since the onset of illness. Social anhedonia plays as a mediator between the altered topological profile of brain network and the progression of schizophrenia. 
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Background: The significant proportion of schizophrenia patients refractory to treatment targeting the dopamine system suggests that more than one mechanism may cause psychotic symptoms. Reinforcement learning tasks have frequently been employed in schizophrenia to assess dopaminergic functioning and reward processing, but studies have not directly compared groups of treatment-refractory and non-refractory patients. Methods: In the current functional magnetic resonance imaging study 21 patients with treatment resistant schizophrenia (TRS), 21 patients with non-treatment resistant schizophrenia (NTR), and 24 healthy controls (HC) performed a probabilistic reinforcement learning task, utilising emotionally valenced face stimuli which elicit a social bias toward happy faces. Behavior was characterized with a reinforcement learning model. Trial-wise reward prediction error (RPE) signaling and the differential impact of emotional bias on these reward signals were compared between groups. Results: Patients showed impaired reinforcement learning relative to controls, while all groups demonstrated an emotional bias favouring selection of the happy faces. The pattern of RPE signaling was similar in HC and TRS groups, whereas NTR patients showed significant attenuation of RPE-related activation. The TRS patients differed from the NTR patients in the relationship between emotional bias and subcortical RPE signal during negative feedback. Discussion: TRS can be dissociated from NTR on the basis of a different neural mechanism underlying their symptoms. The data support the hypothesis that a favourable response to antipsychotic treatment may be contingent on dopaminergic dysfunction, characterized by aberrant RPE signaling, whereas treatment resistance may be characterized by an abnormality in distinct cognitive mechanisms interacting with this response. Background: Recent research suggests that individuals at ultra-high risk for psychosis (UHR) show altered resting cerebral blood flow (rCBF) in key regions linked to psychosis pathophysiology: the hippocampus, midbrain, and basal ganglia. Greater perturbations in basal ganglia rCBF were correlated with positive psychotic symptoms, while remission from the UHR state was associated with a longitudinal normalization of hippocampal rCBF. Oxytocin -a neuropeptide with potential anxiolytic and prosocial properties-is currently under investigation as a novel therapeutic for a number of neuropsychiatric disorders. Previous work conducted in healthy males demonstrated that a single acute dose of intranasal oxytocin had marked effects on rCBF across all of the aforementioned regions (hippocampus, basal ganglia, midbrain), as well as the amygdala, anterior cingulate cortex and cerebellum -regions where neurofunctional alterations have been previously reported in UHR groups. Despite these findings, no studies have yet examined the effects of intranasal oxytocin on resting perfusion in UHR individuals. Methods: In a double-blind, placebo-controlled, crossover design, 30 UHR males underwent two MRI scans at 3 Tesla, once after 40IU intranasal oxytocin and once after matched placebo (one-week wash-out). Arterial spin labeling (ASL) was used to measure rCBF starting approximately 22 minutes post-intranasal administration. The severity of attenuated psychotic symptoms was assessed using the Comprehensive Assessment of At-Risk Mental States (CAARMS). Measures of social cognition, emotional processing and level of functioning were also acquired. We hypothesized that relative to placebo, a single acute dose of intranasal oxytocin would modulate rCBF in the hippocampus, basal ganglia and midbrain, and that this effect would be greater in those with more severe baseline deficits in social and emotional functioning. Results: Data analysis is currently ongoing and the results will be presented at the conference. Discussion: These results will provide physiological evidence for a potential first-in-class intervention for UHR patients. Given the current lack of evidence for effective treatments in this patient group, better understanding of the neural correlates of the high-risk state and the physiological basis for the effects of novel therapeutics is desperately warranted. Background: Insufficient response to antipsychotics constitutes a challenge in the treatment of patients suffering from schizophrenia. Treatment resistances have been linked to a normal striatal dopamine system. We aim to stratify antipsychotic-naïve first-episode patients based on striatal dopamine synthesis capacity (DSC) measured with positron emission tomography (PET). We hypothesize that patients who respond to treatment have an increased DSC at baseline compared to non-responders and healthy controls (HC). Methods: The current data have been collected as a part of a multimodal first episode study. Patients are examined before and after 6 weeks treatment with flexible doses of Aripiprazole. PET: Dynamic scans are performed in an integrated PET-CT scanner using the tracer 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-FDOPA). Duration of scanning is two times one hour, with half an hour break.
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